Cargando…
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
Tumor indoleamine 2,3-dioxygenase (IDO) promotes immunosuppression by direct action on effector T cells and Tregs and through recruitment, expansion and activation of myeloid-derived suppressor cells (MDSCs). Targeting of MDSCs is clinically being explored as a therapeutic strategy, though optimal t...
Autores principales: | Holmgaard, Rikke B., Zamarin, Dmitriy, Lesokhin, Alexander, Merghoub, Taha, Wolchok, Jedd D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856741/ https://www.ncbi.nlm.nih.gov/pubmed/27211548 http://dx.doi.org/10.1016/j.ebiom.2016.02.024 |
Ejemplares similares
-
Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
por: Holmgaard, Rikke B, et al.
Publicado: (2014) -
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013) -
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013) -
Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013) -
Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013)